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Conclusion: Despite higher risk profile, Japanese women treated with PES tended to
have better clinical outcome than PES-treated men at 1 year.
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Background: Bivalirudin is associated with superior safety and economic outcomes
with similar efficacy over heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) in
percutaneous intervention (PCI). While gender and diabetes are significant drivers of
clinical and economic outcomes, it is unclear if bivalirudin maintains its advantages
over heparin plus GPI in an unselected group of these high-risk patients.
Methods: Using the Premier Perspective Database, one of the largest administrative
US databases of hospital clinical and economic outcomes, female patients with diabetes
who had undergone PCI between 2004 and 2010 were identified. Primary endpoints
of in-hospital mortality, clinically apparent bleeding, post-PCI length of stay, and
hospitalization costs were compared between patients treated with bivalirudin versus
heparin plus GPI. Data were unadjusted and propensity score matched.
Results: Data from 61,791 diabetic women was examined in the unadjusted population.
Women over 70 years of age and those pre-treated with clopidogrel were more likely
to receive bivalirudin (61% and 64%, respectively; p<0.03); whereas those with STEMI
or shock were more likely to be treated with heparin plus GPI (81% and 78%
respectively; p<0.01). In-hospital mortality and all bleeding parameters were lower in
the bivalirudin group. In contrast, post-PCI length of stay and total adjusted hospital
costs were significantly greater in the heparin group. When a propensity score matching
method was used to minimize baseline differences between comparison groups, all
clinical and economic outcomes remained significantly lower in the bivalirudin-treated
female diabetics, table 1.
“BIV” = Bivalirudin
“HEP + GPI” = Heparin plus glycoprotein IIb/IIIa inhibitor
“PCI” = percutaneous intervention
“US” = United States
Conclusion: In this large population of high-risk patients, real-world bivalirudin use
in diabetic women undergoing PCI is associated with lower rates of in-hospital
mortality, bleeding, transfusion, post-PCI length of stay, and lower hospitalization costs
compared with the use of heparin plus GPI in unadjusted and propensity score matched
populations.
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Background: The impact of gender on the long-term (greater than 1 year) outcomes
of patients with acute myocardial infarction who have undergone primary PCI is not
well established.
Methods: We examined 3 year outcomes from the large-scale, randomized
HORIZONS-AMI trial according to sex. We used Cox proportional-hazards methods
with stepwise selection using entry and exit criteria of p <0.1 to determine the
independent predictors of MACE, major bleeding and death. Candidate variables tested
were sex; age; diabetes; hypertension; history of smoking; prior MI; prior PCI; prior
CABG; Killip class >1; baseline anemia; creatinine; and symptom onset to balloon
time.
Results: Compared with men, women were significantly older and had higher
prevalence of hypertension and hyperlipidemia (all p<0.05). In contrast, women were
less likely to have a prior history of MI, PCI, CABG and were less likely to be smokers
(all p<0.05). Women were less likely to undergo primary PCI in favor of medical
management (p<0.05). They had longer symptom to balloon time (p=0.007). Female
gender was associated with increased MACE, death and major bleeding at 3 year
follow-up (Table). After multivariable analysis female gender remained an independent
predictor of major bleeding, but not of MACE or death.
Patient Outcomes at 3 years
MACE = Major adverse cardiovascular events, composite of death, reinfarction,
stroke, ischemic TVR; CABG= coronary artery bypass graft; TVR = target vessel
revascularization; ST = stent thrombosis
Conclusion: In the HORIZONS-AMI trial, women had a more unfavorable
cardiovascular risk profile compared with men. Female gender was an independent
predictor of long-term major bleeding (HR[95%CI] = 1.77 [1.38, 2.27], P<0.0001, but
not of death (0.92 [0.68, 1.26], P=0.62) or overall MACE (1.17 [0.98, 1.40], P=0.08).
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Background: Although female patients are at high risk for unfavorable outcomes after
STEMI, the independent predictors of major adverse cardiac events (MACE) at long
term follow up have not been described.
Methods: We examined 3-year outcomes of female patients (n=842) from the large-
scale, prospective, multicenter, HORIZONS-AMI trial where patients were randomized
to receive heparin plus glycoprotein IIb/IIIa inhibitor or bivalirudin, and paclitaxel
eluting stents or bare metal stents in a 2 by 2 factorial design. After the performance
of univariate analysis, we used Cox proportional-hazards methods with stepwise
selection using entry and exit criteria of p<0.1 to determine the independent predictors
of MACE, mortality and reinfarction. Candidate variables tested were age,
hypertension, diabetes, history of smoking, peripheral vascular disease, family history
of premature CAD, prior MI, prior PCI, prior CABG, Killip Class on presentation, and
door to balloon time.
Results: The median age was 66 (95% CI 57.1-75.3), 51% were smokers, 19% had
diabetes, 3.3% had chronic renal insufficiency. The 3- year rates of mortality,
reinfarction and MACE were 8.2%, 7.1% and 24% respectively. The table summarizes
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